Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2021

Brønsted Acid-Promoted Hydroamination of Unsaturated Hydrazones via an Ionic Pathway: Access to Biologically Important 5-Arylpyrazolines

Han He, Ning Xu, Honglin Zhang, Bin Chen, Zhengnan Hu, Kang Guo, Jianlin Chun, Shujun Cao, and Yingguang Zhu*

Jiangsu Key Laboratory of Pesticide Science and Department of Chemistry, College of Sciences, Nanjing Agricultural University, Nanjing 210095, China

E-mail: ygzhu@njau.edu.cn

Supporting Information

Table of Contents

General information	
General procedure for the hydroamination reaction	
Mechanistic studies	S2
Characterization data	
X-ray structure of product 2e	S17
References	S18
NMR spectra	

General information. All commercially available reagents were used without further purification. Column chromatography was performed on silica gel (200-300 mesh). ¹H NMR (400 MHz) and ¹³C NMR (100 MHz) spectra were recorded on a 400 MHz spectrometer. Chemical shifts (δ) were reported in ppm, and coupling constants (*J*) were given in Hertz (Hz). Data were reported as s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet. High-resolution mass spectra (HRMS) were recorded on an AB SCIEX Triple TOF 5600+ mass spectrometer. Melting points were uncorrected. Alkenyl hydrazone substrates **1a–1ac** were prepared according to the reported methods.¹⁻⁴

General procedure for the hydroamination reaction (Scheme 2). To a reaction tube equipped with a magnetic stir bar were added alkenyl hydrazone 1 (0.20 mmol), conc. H₂SO₄ (11 μ L, 0.20 mmol), and CH₃CN (2.0 mL). The reaction mixture was stirred at 50 °C under nitrogen atmosphere for 12 h, cooled to room temperature, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 10:1) to give product 2.

Mechanistic studies

The experiment of the addition of radical scavenger BHT (Scheme 3a). To a reaction tube equipped with a magnetic stir bar were added alkenyl hydrazone 1a (78.1 mg, 0.20 mmol), conc. H₂SO₄ (11 μ L, 0.20 mmol), BHT (121.2 mg, 0.60 mmol), and CH₃CN (2.0 mL). The reaction mixture was stirred at 50 °C under nitrogen atmosphere for 12 h, cooled to room temperature, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 10:1) to give product 2a (71.5 mg, 92%) as a white solid. The addition of a radical scavenger did not inhibit the reaction, still generating product 2a in 92% yield, which indicated a radical pathway might not be involved in the reaction process.

Procedure for the preparation of intermediates *Z*-3 and *E*-3 from 1a (Scheme 3b). To a reaction tube equipped with a magnetic stir bar were added alkenyl hydrazone 1a (781.2 mg, 2.0 mmol), conc. H₂SO₄ (110 μ L, 2.0 mmol), and CH₃CN (20.0 mL). The reaction mixture was stirred at 50 °C under nitrogen atmosphere for a much shorter reaction time (0.5 h). Thin-layer chromatography (TLC) analysis indicated that substrate 1a was completely consumed, and pyrazoline 2a was not observed. The crude reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 20:1 ~ 10:1) to afford intermediate product *Z*-3 (228.6 mg, 29%, white solid) and *E*-3 (443.2 mg, 57%, white solid).

Procedure for the preparation of pyrazoline product 2a from intermediate Z-3 (Scheme 3c).

To a reaction tube equipped with a magnetic stir bar were added Z-3 (78.1 mg, 0.20 mmol), conc. H₂SO₄ (11 μ L, 0.20 mmol), and CH₃CN (2.0 mL). The reaction mixture was stirred at 50 °C under nitrogen atmosphere for 12 h, cooled to room temperature, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 10:1) to give product **2a** (70.1 mg, 90%) as a white solid.

Procedure for the preparation of pyrazoline product 2a from intermediate *E*-3 (Scheme 3c).

To a reaction tube equipped with a magnetic stir bar were added *E*-**3** (78.1 mg, 0.20 mmol), H₂SO₄ (11 μ L, 0.20 mmol), and CH₃CN (2.0 mL). The reaction mixture was stirred at 50 °C under nitrogen atmosphere for 12 h, cooled to room temperature, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 10:1) to provide product **2a** (65.3 mg, 84%) as a white solid.

The investigation of the formation of pyrazoline product 2a from the intermediate Z-3 or E-3 in the absence of H_2SO_4 (Scheme 3d).

To a reaction tube equipped with a magnetic stir bar were added Z-3 or E-3 (78.1 mg, 0.20 mmol) and CH₃CN (2.0 mL). The reaction mixture was stirred at 50 °C under nitrogen atmosphere for 12 h and cooled to room temperature. Thin-layer chromatography (TLC) analysis indicated that the intermediate Z-3 or E-3 kept intact, and the formation of product 2a was not observed. The results suggest that the Brønsted acid plays an important role in the formation of the pyrazoline product from the intermediate.

Characterization data

5-methyl-3,5-diphenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2a)



White solid (73.7 mg, 94%); mp 81–83 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.75 – 7.66 (m, 2H) 7.58 (d, J = 8.2 Hz, 2H), 7.45 – 7.38 (m, 3H), 7.36 – 7.30 (m, 2H), 7.27 – 7.19 (m, 3H), 7.14 (d, J = 8.1 Hz, 2H), 3.50 (d, J = 17.2 Hz, 1H), 3.37 (d, J = 17.2 Hz, 1H), 2.37 (s, 3H), 2.03 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 152.5, 143.4, 143.0, 136.9, 131.1, 130.1, 129.0, 128.6, 128.2, 127.60, 127.55, 126.5, 125.8, 71.8, 52.8, 25.2, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₃H₂₃N₂O₂S 391.1475, found 391.1478.

3-(4-methoxyphenyl)-5-methyl-5-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2b)



White solid (71.1 mg, 85%); mp 109–110 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, J = 8.8 Hz, 2H), 7.57 (d, J = 8.2 Hz, 2H), 7.33 (dd, J = 7.6, 2.1 Hz, 2H), 7.25 – 7.18 (m, 3H), 7.13 (d, J = 8.2 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 3.84 (s, 3H), 3.46 (d, J = 17.1 Hz, 1H), 3.34 (d, J = 17.1 Hz, 1H), 2.36 (s, 3H), 2.01 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 161.1, 152.3, 143.5, 142.9, 136.9, 128.9, 128.2, 128.1, 127.6, 127.5, 125.8, 123.8, 114.0, 71.6, 55.4, 53.0, 25.2, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₄H₂₅N₂O₃S 421.1580, found 421.1582.

5-methyl-5-phenyl-3-(*p*-tolyl)-1-tosyl-4,5-dihydro-1*H*-pyrazole (2c)



White solid (70.1 mg, 87%); mp 146–147 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 8.3 Hz, 2H), 7.32 (dd, J = 7.7, 1.8 Hz, 2H), 7.25 – 7.18 (m, 5H), 7.12 (d, J = 8.1 Hz, 2H), 3.48 (d, J = 17.2 Hz, 1H), 3.35 (d, J = 17.2 Hz, 1H), 2.39 (s, 3H), 2.36 (s, 3H), 2.02 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 152.6, 143.4, 143.0, 140.4, 136.9, 129.3, 128.9, 128.3, 128.2, 127.6, 127.5, 126.5, 125.8, 71.6, 52.9, 25.3, 21.48, 21.45; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₄H₂₅N₂O₂S 405.1631, found 405.1634.

3-(4-chlorophenyl)-5-methyl-5-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2d)



White solid (71.1 mg, 84%); mp 130–132 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.62 (d, J = 8.6 Hz, 2H), 7.56 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.6 Hz, 2H), 7.32 (dd, J = 7.6, 2.0 Hz, 3H), 7.27 – 7.19 (m, 2H), 7.15 (d, J = 8.1 Hz, 2H), 3.46 (d, J = 17.2 Hz, 1H), 3.34 (d, J = 17.2 Hz, 1H), 2.37 (s, 3H), 2.03 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 151.3, 143.3, 143.2, 136.8, 136.0, 129.6, 129.0, 128.8, 128.3, 127.7, 127.64, 127.58, 125.7, 72.1, 52.7, 25.3, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₃H₂₂ClN₂O₂S 425.1085, found 425.1083.

3-(4-bromophenyl)-5-methyl-5-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2e)



White solid (89.5 mg, 95%); mp 133–135 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.59 – 7.50 (m, 6H), 7.31 (dd, J = 7.6, 1.9 Hz, 2H), 7.28 – 7.20 (m, 3H), 7.14 (d, J = 8.1 Hz, 2H), 3.46 (d, J = 17.2 Hz, 1H), 3.34 (d, J = 17.2 Hz, 1H), 2.37 (s, 3H), 2.03 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 151.4, 143.3, 143.2, 136.8, 131.8, 130.1, 129.0, 128.3, 127.9, 127.7, 127.6, 125.7, 124.4, 72.1, 52.7, 25.3, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₃H₂₂BrN₂O₂S 469.0580, found 469.0580.

5-methyl-5-phenyl-1-tosyl-3-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-pyrazole (2f)



White solid (77.2 mg, 84%); mp 133–134 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, J = 8.2 Hz, 2H), 7.63 (d, J = 8.3 Hz, 2H), 7.55 (d, J = 8.3 Hz, 2H), 7.31 (dd, J = 7.7, 1.8 Hz, 2H), 7.26 – 7.18 (m, 3H), 7.14 (d, J = 8.1 Hz, 2H), 3.49 (d, J = 17.3 Hz, 1H), 3.38 (d, J = 17.3 Hz, 1H), 2.36 (s, 3H), 2.03 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 151.0, 143.3, 143.1, 136.7, 134.4, 131.4 (q, J = 33.0 Hz), 129.0, 128.3, 127.7, 127.5,

126.6, 125.6, 125.4 (q, J = 4.0 Hz), 123.7 (q, J = 270.0 Hz), 72.3, 52.5, 25.2, 21.4; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₄H₂₂F₃N₂O₂S 459.1349, found 459.1348.

3-(3-chlorophenyl)-5-methyl-5-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2g)



Yellow oil (84.0 mg, 99%); ¹H NMR (400 MHz, CDCl₃) δ 7.69 (s, 1H), 7.55 (t, J = 9.2 Hz, 3H), 7.39 – 7.31 (m, 3H), 7.31 (d, J = 2.0 Hz, 1H), 7.28 – 7.20 (m, 3H), 7.16 (d, J = 8.1 Hz, 2H), 3.47 (d, J = 17.3 Hz, 1H), 3.34 (d, J = 17.3 Hz, 1H), 2.38 (s, 3H), 2.04 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 151.1, 143.2, 136.8, 134.7, 132.9, 130.0, 129.9, 129.1, 128.3, 127.7, 127.6, 126.4, 125.7, 124.6, 72.1, 52.7, 25.3, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₃H₂₂ClN₂O₂S 425.1085, found 425.1087.

5-methyl-5-phenyl-3-(o-tolyl)-1-tosyl-4,5-dihydro-1*H*-pyrazole (2h)



Yellow oil (59.2 mg, 73%); ¹H NMR (400 MHz, CDCl₃) δ 7.58 (d, J = 8.1 Hz, 2H), 7.36 (dd, J = 6.5, 2.8 Hz, 2H), 7.29 – 7.21 (m, 6H), 7.19 (dd, J = 8.1, 4.3 Hz, 1H), 7.14 (d, J = 8.2 Hz, 2H), 3.54 (d, J = 17.0 Hz, 1H), 3.40 (d, J = 17.0 Hz, 1H), 2.65 (s, 3H), 2.37 (s, 3H), 2.04 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 153.3, 143.6, 143.2, 138.1, 136.6, 131.8, 129.8, 129.3, 128.9, 128.5, 128.3, 127.9, 127.5, 125.8, 70.8, 55.1, 25.0, 23.6, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₄H₂₅N₂O₂S 405.1631, found 405.1633.

3-(2-chlorophenyl)-5-methyl-5-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2i)



White solid (71.8 mg, 85%); mp 116–118 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.77 – 7.68 (m, 1H), 7.59 (d, J = 8.2 Hz, 2H), 7.43 – 7.33 (m, 3H), 7.33 – 7.27(m,2H), 7.25 (q, J = 3.7 Hz, 3H), 7.15 (d, J = 8.1 Hz, 2H), 3.66 (d, J = 17.6 Hz, 1H), 3.54 (d, J = 17.6 Hz, 1H), 2.37 (s, 3H), 2.01 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 152.3, 143.2, 143.2, 136.8, 132.6, 130.7, 130.6, 130.4, 130.3, 128.9, 128.2, 127.7, 127.6, 126.8, 125.7, 72.5, 55.5, 24.8, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₃H₂₂ClN₂O₂S 425.1085, found 425.1085.

5-methyl-3-(naphthalen-2-yl)-5-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2j)



White solid (77.5 mg, 88%); mp 169–170 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.08 (dd, J = 8.7, 1.6 Hz, 1H), 7.92 – 7.83 (m, 3H), 7.83 – 7.78 (m, 1H), 7.60 (d, J = 8.3 Hz, 2H), 7.56 – 7.46 (m, 2H), 7.35 (dd, J = 7.7, 1.9 Hz, 2H), 7.29 – 7.19 (m, 3H), 7.15 (d, J = 8.1 Hz, 2H), 3.64 (d, J = 17.1 Hz, 1H), 3.51 (d, J = 17.1 Hz, 1H), 2.36 (s, 3H), 2.07 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 152.6, 143.4, 143.1, 136.9, 134.0, 132.9, 129.0, 128.8, 128.4, 128.31, 128.29, 127.8, 127.64, 127.62, 127.2, 126.71, 126.69, 125.8, 123.5, 72.0, 52.8, 25.4, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₇H₂₅N₂O₂S 441.1631, found 441.1632.

5-methyl-5-phenyl-3-(thiophen-2-yl)-1-tosyl-4,5-dihydro-1*H*-pyrazole (2k)



White solid (63.9 mg, 81%); mp 162–163 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.55 (d, J = 8.1 Hz, 2H), 7.41 (d, J = 5.0 Hz, 1H), 7.32 (d, J = 6.4 Hz, 2H), 7.28 – 7.18 (m, 3H), 7.13 (d, J = 7.8 Hz, 3H), 7.07 – 7.00 (m, 1H), 3.48 (d, J = 17.0 Hz, 1H), 3.36 (d, J = 17.0 Hz, 1H), 2.36 (s, 3H), 2.01 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 148.4, 143.1, 143.0, 136.7, 134.7, 128.9, 128.6, 128.2, 128.1, 127.6, 127.4, 125.8, 72.0, 53.4, 25.2, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₁H₂₁N₂O₂S₂ 397.1039, found 397.1040.

5-methyl-3-pentyl-5-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (21)



Yellow oil (75.6 mg, 98%); ¹H NMR (400 MHz, CDCl₃) δ 7.54 (d, J = 8.3 Hz, 2H), 7.34 – 7.27 (m, 2H), 7.25 – 7.19(m, 3H), 7.14 (d, J = 8.1 Hz, 2H), 3.04 (d, J = 17.6 Hz, 1H), 2.91 (d, J = 17.6 Hz, 1H), 2.38 (s, 3H), 2.34 (t, J = 7.7 Hz, 2H), 1.88 (s, 3H),1.61 – 1.49 (m, 2H), 1.38 – 1.23 (m, 4H), 0.88 (t, J = 6.9 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 157.5, 143.7, 142.8, 137.1, 128.8, 128.1, 127.5, 127.3, 125.6, 70.8, 55.2, 31.3, 30.0, 25.8, 24.9, 22.3, 21.4, 13.9; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₂H₂₉N₂O₂S 385.1944, found 385.1947.

3-isopropyl-5-methyl-5-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2m)



White solid (63.6 mg, 89%); mp 121–123 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.53 (d, J = 8.3 Hz, 2H), 7.32 – 7.26 (m, 2H), 7.25 – 7.18 (m, 3H), 7.13 (d, J = 8.1 Hz, 2H), 3.04 (d, J = 17.5 Hz, 1H), 2.92 (d, J = 17.5 Hz, 1H), 2.75 – 2.62 (m, 1H), 2.37 (s, 3H), 1.86 (s, 3H), 1.15 (d, J = 6.9 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 161.9, 143.6,

142.7, 136.9, 128.7, 128.0, 127.5, 127.2, 125.5, 70.9, 52.9, 29.7, 24.6, 21.4, 19.8, 19.7; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₀H₂₅N₂O₂S 357.1631, found 357.1633.

3-cyclopropyl-5-methyl-5-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2n)



White solid (45.7 mg, 65%); mp 100–101 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.52 (d, J = 8.1 Hz, 2H), 7.33 – 7.27 (m, 2H), 7.25 – 7.20 (m, 3H), 7.14 (d, J = 8.0 Hz, 2H), 2.88 (d, J = 17.2 Hz, 1H), 2.75 (d, J = 17.2 Hz, 1H), 2.38 (s, 3H), 1.90 (s, 3H), 1.86 – 1.76 (m, 1H), 0.96 – 0.82 (m, 2H), 0.80 – 0.66 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 159.0, 143.5, 142.8, 136.9, 128.9, 128.1, 127.6, 127.4, 125.6, 70.7, 52.7, 24.8, 21.5, 11.5, 6.5, 6.3; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₀H₂₃N₂O₂S 355.1475, found 355.1472.

3-cyclopentyl-5-methyl-5-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (20)



White solid (71.1 mg, 90%); mp 48–49 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.53 (d, J = 8.0 Hz, 2H), 7.33 – 7.27 (m, 2H), 7.25 – 7.18 (m, 3H), 7.13 (d, J = 8.0 Hz, 2H), 3.05 (d, J = 17.4 Hz, 1H), 2.91 (d, J = 17.4 Hz, 1H), 2.87 – 2.78 (m, 1H), 2.38 (s, 3H), 1.87 – 1.81 (m, 5H), 1.74 – 1.52 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 160.4, 143.7, 142.8, 137.0, 128.8, 128.1, 127.6, 127.3, 125.6, 70.9, 53.7, 40.4, 30.2, 30.1, 25.3, 24.7, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₂H₂₇N₂O₂S 383.1788, found 383.1789.

3-cyclohexyl-5-methyl-5-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2p)



White solid (77.5 mg, 98%); mp 97–98 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.52 (d, J = 8.3 Hz, 2H), 7.31 – 7.25 (m, 2H), 7.24 – 7.16 (m, 3H), 7.12 (d, J = 8.0 Hz, 2H), 3.04 (d, J = 17.5 Hz, 1H), 2.91 (d, J = 17.5 Hz, 1H), 2.44 – 2.39 (m, 1H), 2.37 (s, 3H), 1.87 (s, 3H), 1.86 – 1.64 (m, 5H), 1.41 – 1.17 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 161.1, 143.6, 142.7, 137.0, 128.8, 128.1, 127.5, 127.3, 125.6, 70.6, 53.4, 39.2, 30.1, 30.0, 25.8, 25.63, 25.61, 24.8, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₃H₂₉N₂O₂S 397.1944, found 397.1946.

3-(tert-butyl)-5-methyl-5-phenyl-1-tosyl-4,5-dihydro-1H-pyrazole (2q)



White solid (63.7 mg, 86%); mp 83–85 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.55 (d, J = 8.3 Hz, 2H), 7.32 – 7.27 (m, 2H), 7.24 – 7.20 (m, 3H), 7.14 (d, J = 8.0 Hz, 2H), 3.07 (d, J = 17.3 Hz, 1H), 2.94 (d, J = 17.3 Hz, 1H), 2.38 (s, 3H), 1.84 (s, 3H), 1.18 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 164.1, 143.7, 142.8, 137.0, 128.7, 128.1, 127.7, 127.3, 125.6, 71.5, 52.1, 34.1, 27.8, 24.5, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₁H₂₇N₂O₂S 371.1788, found 371.1785.

5-methyl-3-phenyl-5-(p-tolyl)-1-tosyl-4,5-dihydro-1*H*-pyrazole (2r)



White solid (78.8 mg, 97%); mp 137–138 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.75 – 7.67 (m, 2H), 7.57 (d, J = 8.3 Hz, 2H), 7.45 – 7.37 (m, 3H), 7.21 (d, J = 8.2 Hz, 2H), 7.13 (d, J = 8.1 Hz, 2H), 7.01 (d, J = 8.0 Hz, 2H), 3.49 (d, J = 17.2 Hz, 1H), 3.36 (d, J

= 17.2 Hz, 1H), 2.37 (s, 3H), 2.33 (s, 3H), 2.01 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 152.5, 142.9, 140.4, 137.3, 136.9, 131.1, 130.1, 128.82, 128.79, 128.6, 127.5, 126.5, 125.7, 71.7, 52.7, 25.3, 21.5, 21.0; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₄H₂₅N₂O₂S 405.1631, found 405.1630.

5-(4-chlorophenyl)-5-methyl-3-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2s)



White solid (83.5 mg, 98%); mp 70–71 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.75 – 7.63 (m, 2H), 7.58 (d, J = 8.3 Hz, 2H), 7.45 – 7.38 (m, 3H), 7.28 – 7.21 (m, 2H), 7.20 – 7.12 (m, 4H), 3.45 (d, J = 17.2 Hz, 1H), 3.37 (d, J = 17.2 Hz, 1H), 2.38 (s, 3H), 2.01 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 152.5, 143.3, 141.9, 136.7, 133.6, 130.9, 130.3, 129.0, 128.7, 128.3, 127.5, 127.2, 126.5, 71.3, 52.6, 25.2, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₃H₂₂ClN₂O₂S 425.1085, found 425.1083.

5-(4-bromophenyl)-5-methyl-3-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2t)



White solid (89.6 mg, 95%); mp 67–69 °C; ¹H NMR (400 MHz, CDCl) δ 7.74 – 7.67 (m, 2H), 7.58 (d, J = 8.4 Hz, 2H), 7.45 – 7.38 (m, 3H), 7.34 – 7.27 (m, 2H), 7.21 – 7.13 (m, 4H), 3.45 (d, J = 17.2 Hz, 1H), 3.37 (d, J = 17.2 Hz, 1H), 2.39 (s, 3H), 2.00 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 152.6, 143.3, 142.3, 136.6, 131.2, 130.8, 130.3, 129.0, 128.6, 127.5, 127.4, 126.5, 121.7, 71.3, 52.5, 25.1, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₃H₂₂BrN₂O₂S 469.0580, found 469.0578.

5-(4-fluorophenyl)-5-methyl-3-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2u)



White solid (80.2 mg, 98%); mp 130–131 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.74 – 7.66 (m, 2H), 7.58 (d, *J* = 8.3 Hz, 2H), 7.45 – 7.37 (m, 3H), 7.33 – 7.26 (m, 2H), 7.16 (d, *J* = 8.1 Hz, 2H), 6.95 – 6.82 (m, 2H), 3.47 (d, *J* = 17.2 Hz, 1H), 3.37 (d, *J* = 17.2 Hz, 1H), 2.37 (s, 3H), 2.02 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 162.1 (d, *J* = 245.0 Hz), 152.5, 143.3, 139.3 (d, *J* = 3.0 Hz), 136.8, 131.1, 130.2, 129.0, 128.6, 127.6 (d, *J* = 8.0 Hz), 127.5, 126.5, 115.0 (d, *J* = 21.0 Hz), 71.3, 52.7, 25.5, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₃H₂₂FN₂O₂S 409.1381, found 409.1382.

5-(3,4-dichlorophenyl)-5-methyl-3-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2v)



White solid (77.7 mg, 85%); mp 152–153 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.74 – 7.65 (m, 2H), 7.60 (d, J = 8.1 Hz, 2H), 7.47 – 7.38 (m, 3H), 7.33 – 7.27 (m, 2H), 7.24 – 7.15 (m, 3H), 3.44 (d, J = 17.3 Hz, 1H), 3.38 (d, J = 17.3 Hz, 1H), 2.39 (s, 3H), 1.99 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 152.5, 143.7, 143.5, 136.4, 132.4, 131.9, 130.7, 130.4, 130.1, 129.2, 128.7, 128.0, 127.4, 126.6, 125.3, 70.8, 52.2, 25.1, 21.6; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₃H₂₁Cl₂N₂O₂S 459.0695, found 459.0695.

5-methyl-5-(naphthalen-2-yl)-3-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2w)



White solid (80.4 mg, 91%); mp 174–176 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.82 – 7.70 (m, 5H), 7.63 (d, J = 8.7 Hz, 1H), 7.55 – 7.46 (m, 4H), 7.46 – 7.41 (m, 3H), 7.36 (d, J = 8.7, 2.0 Hz, 1H), 6.95 (d, J = 8.1 Hz, 2H), 3.60 (d, J = 17.3 Hz, 1H), 3.44 (d,

J = 17.3 Hz, 1H), 2.29 (s, 3H), 2.17 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 152.6, 143.0, 140.2, 136.7, 132.7, 132.6, 131.1, 130.1, 128.8, 128.6, 128.3, 128.0, 127.4, 127.3, 126.5, 126.2, 126.1, 124.6, 123.9, 71.8, 52.6, 25.4, 21.4; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₇H₂₅N₂O₂S 441.1631, found 441.1630.

5,5-dimethyl-3-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2x)



White solid (39.1 mg, 60%); mp 53-55 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, J = 8.3 Hz, 2H), 7.68 – 7.61 (m, 2H), 7.43 – 7.34 (m, 3H), 7.27 (d, J = 10.3 Hz, 2H), 3.04 (s, 2H), 2.40 (s, 3H), 1.56 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 153.4, 143.4, 137.3, 131.4, 130.0, 129.2, 128.5, 128.1, 126.4, 69.1, 49.2, 27.1, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₁₈H₂₁N₂O₂S 329.1318, found 329.1315.

5-cyclohexyl-5-methyl-3-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (2y)



White solid (55.4 mg, 72%); mp 57–58 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.92 (d, J = 8.3 Hz, 2H), 7.70 – 7.62 (m, 2H), 7.44 – 7.33 (m, 3H), 7.28 (d, J = 8.2 Hz, 2H), 3.22 (d, J = 17.0 Hz, 1H), 2.66 (d, J = 17.0 Hz, 1H), 2.39 (s, 3H), 2.36 – 2.18 (m, 1H), 1.92 – 1.77 (m, 3H), 1.77 – 1.66 (m, 2H), 1.42 (s, 3H), 1.26 – 1.30 (m, 1H), 1.30 – 1.24 (m, 1H), 1.15 – 1.04 (m, 1H), 0.94 – 0.82 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 152.7, 143.2, 137.6, 131.4, 129.8, 129.2, 128.4, 127.8, 126.3, 75.9, 45.2, 42.4, 28.4, 27.6, 26.3, 26.3, 25.8, 24.3, 21.5; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₃H₂₉N₂O₂S 397.1944, found 397.1943.

5-methyl-1,3,5-triphenyl-4,5-dihydro-1*H*-pyrazole (2ab)



Yellow solid (39.5 mg, 63%); mp 166–167 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.76 – 7.69 (m, 2H), 7.57 – 7.49 (m, 2H), 7.43 – 7.37 (m, 4H), 7.36 – 7.29 (m, 2H), 7.14 – 7.09 (m, 2H), 7.06 – 6.99 (m, 2H), 6.82 – 6.74 (m, 1H), 3.44 (d, *J* = 16.8 Hz, 1H), 3.43 (d, *J* = 16.8 Hz, 1H), 1.82 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 145.9, 145.2, 143.6, 133.0, 129.0, 128.6, 128.5, 128.4, 127.2, 125.6, 125.5, 119.4, 115.3, 69.9, 53.5, 22.2; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₂H₂₀N₂ 312.1626, found 312.1628. **5-methyl-3,5-diphenyl-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1***H***-pyrazole (2ac)**



Yellow solid (76.8 mg, 92%); mp 127–128 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.75 – 7.67 (m, 2H), 7.48 – 7.43 (m, 2H), 7.42 – 7.35 (m, 3H), 7.33 – 7.21 (m, 5H), 3.63 (d, J = 16.7 Hz, 1H), 3.49 (d, J = 16.7 Hz, 1H), 1.77 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 150.5, 145.4, 138.2, 137.0, 132.8, 132.3, 128.8, 128.6, 128.0, 127.1, 125.92, 125.85, 70.9, 51.4, 24.0; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₂H₁₈Cl₃N₂ 415.0530, found 415.0533.

1-(5-methyl-3,5-diphenyl-4,5-dihydro-1*H*-pyrazol-1-yl)ethan-1-one (2ad)



White solid (34.1 mg, 61%); mp 146–147 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.74 – 7.68 (m, 2H), 7.46 – 7.39 (m, 3H), 7.37 – 7.28 (m, 4H), 7.28 – 7.21 (m, 1H), 3.46 (d, J = 17.6 Hz, 1H), 3.40 (d, J = 17.6 Hz, 1H), 2.42 (s, 3H), 2.07 (s, 3H); ¹³C NMR (100 S15

MHz, CDCl₃) δ 168.8, 151.5, 144.9, 131.5, 130.1, 128.7, 128.6, 127.0, 126.4, 124.4, 67.5, 52.3, 24.5, 23.2; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₁₈H₁₉N₂O 279.1492, found 279.1492.

(5-methyl-3,5-diphenyl-4,5-dihydro-1*H*-pyrazol-1-yl)(phenyl)methanone (2ae)



White solid (49.0 mg, 70%); mp 100–101 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.97 – 7.89 (m, 2H), 7.68 – 7.62 (m, 2H), 7.50 – 7.43 (m, 2H), 7.43 – 7.36 (m, 6H), 7.36 – 7.31 (m, 2H), 7.28 – 7.22 (m, 1H), 3.50 (d, *J* = 17.6 Hz, 1H), 3.43 (d, *J* = 17.6 Hz, 1H), 2.19 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.3, 152.3, 144.7, 135.5, 131.5, 130.6, 130.2, 130.0, 128.69, 128.65, 127.5, 127.1, 126.6, 124.4, 68.8, 51.7, 24.4; HRMS (ESI-TOF) m/z: [M+H]⁺ calcd for C₂₃H₂₁N₂O 341.1648, found 341.1646.

N'-((1*E*,2*Z*)-1,3-diphenylbut-2-en-1-ylidene)-4-methylbenzenesulfonohydrazide (*Z*-3)



White solid (228.6 mg, 29%); mp 157–159 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (s, 1H), 7.68 – 7.62 (m, 2H), 7.58 (d, J = 8.2 Hz, 2H), 7.32 – 7.24 (m, 3H), 7.21 (d, J = 8.2 Hz, 2H), 7.14 – 7.07 (m, 1H), 7.00 (d, J = 4.3 Hz, 4H), 5.92 (s, 1H), 2.41 (s, 3H), 2.33 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 151.1, 147.1, 143.6, 138.8, 135.9, 135.4, 129.5, 129.3, 128.7, 128.4, 128.2, 127.7, 126.9, 126.2, 116.7, 24.8, 21.6; HRMS (ESI-TOF) m/z: [M +H]⁺ calcd for C₂₃H₂₃N₂O₂S 391.1475, found 391.1475.

N'-((1*E*,2*E*)-1,3-diphenylbut-2-en-1-ylidene)-4-methylbenzenesulfonohydrazide⁵ (*E*-3)



White solid (443.2 mg, 57%); mp 99–101 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.00 (s, 1H), 7.92 (d, J = 7.9 Hz, 2H), 7.72 – 7.66 (m, 2H), 7.56 (d, J = 7.8 Hz, 2H), 7.45 – 7.38 (m, 3H), 7.38 – 7.30 (m, 5H), 6.23 (s, 1H), 2.42 (s, 3H), 1.88 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 151.8, 146.2, 144.0, 139.6, 135.7, 135.6, 129.8, 129.5, 128.7, 128.6, 128.4, 127.9, 126.8, 125.8, 115.8, 21.5, 18.1; HRMS (ESI-TOF) m/z: [M + H]⁺ calcd for C₂₃H₂₃N₂O₂S 391.1475, found 391.1478.

X-ray structure of 2e (CCDC 2018227)





Crystal data and structure refinement for 2e

Identification code	2e
Empirical formula	$C_{23}H_{21}BrN_2O_2S$
Formula weight	469.39
Temperature	296(2) K
Wavelength	0.71073 Å
Crystal system	Monoclinic
	S17

Space group	$P2_1/n$	
Unit cell dimensions	a = 12.3545(4) Å	$\alpha = 90^{\circ}$.
	b = 11.9990(4) Å	$\beta = 94.0510(10)^{\circ}.$
	c = 14.3274(6) Å	$\gamma = 90^{\circ}$.
Volume	2118.61(13) Å ³	
Z	4	
Density (calculated)	1.472 Mg/m ³	
Absorption coefficient	2.061 mm ⁻¹	
F(000)	960	
Crystal size	0.320 x 0.250 x 0.220 mm ³	
Theta range for data collection	2.104 to 27.567°.	
Index ranges	-13<=h<=16, -14<=k<=15, -18<=l<=18	
Reflections collected	32627	
Independent reflections	4888 [R(int) = 0.0397]	
Completeness to theta = 25.242°	99.8 %	
Absorption correction	Semi-empirical from equivalents	
Max. and min. transmission	0.7456 and 0.4795	
Refinement method	Full-matrix least-squares on F ²	
Data / restraints / parameters	4888 / 0 / 264	
Goodness-of-fit on F ²	1.016	
Final R indices [I>2sigma(I)]	R1 = 0.0430, $wR2 = 0.1048$	
R indices (all data)	R1 = 0.0672, $wR2 = 0.1167$	
Extinction coefficient	n/a	
Largest diff. peak and hole	$0.675 \text{ and } -0.744 \text{ e.Å}^{-3}$	

References

- (1) Tripathi, C. B.; Mukherjee, S. Org. Lett. 2014, 16, 3368.
- (2) Imai, T.; Nishida, S. Synthesis 1993, 1993, 395.
- (3) Rajam, S.; Jadhav, A. V.; Li, Q.; Sarkar, S. K.; Singh, P. N. D.; Rohr, A.; Pace, T.

C. S.; Li, R.; Krause, J. A.; Bohne, C.; Ault, B. S.; Gudmundsdottir, A. D. J. Org. *Chem.* **2014**, *79*, 9325.

- (4) Hu, X.-Q.; Qi, X.; Chen, J.-R.; Zhao, Q.-Q.; Wei, Q.; Lan, Y.; Xiao, W.-J. *Nat. Chem.* **2016**, *7*, 11188.
- (5) Liu, W.; Wang, H.; Zhao, H; Li, B.; Chen, S. Synlett 2015, 26, 2170.











S23















S30
























2j

















































































940



S66

-1.562


































S76









7.567 7.567 7.548 7.440 7.432 7.420 7.420 7.369 7.369 7.335 7.334 6.225

001 0 N N

ファファ

-1.878 -2.424

